PetVivo Holdings (PETV)
OTHER OTC:PETV
Want to see PETV full AI Analyst Report?
PETV Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EST
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.58 - $1.69
Previous CloseN/A
Volume249.00
Average Volume (3M)21.60K
Market Cap
$27.98M
Enterprise Value$21.72M
Total Cash (Recent Filing)$168.16K
Total Debt (Recent Filing)$70.56K
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding35,017,418
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.91
Price to Sales (P/S)10.86
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue19.53
Enterprise Value/Gross Profit29.58
Enterprise Value/Ebitda-2.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
SaaS High-margin OpportunityThe exclusive 10-year AgenticPet license and PetVivo AI launch create a structural shift toward recurring, high-margin SaaS revenue. Recurring subscriptions with low CapEx materially improve unit economics, diversify revenue away from one-time device sales, and can sustainably lift overall gross margins if monetization executes as described.
Expanded Distribution FootprintMultiple channel and international distribution agreements create durable commercialization leverage. Access to thousands of clinics and regional partners speeds adoption, lowers incremental customer acquisition effort, and supports scalable unit growth for Spryng/PrecisePRP and cross-selling of future SaaS offerings across established veterinary networks.
Regulatory Market AccessRegulatory recognition in Canada establishes official market entry and reduces barriers to adoption in a sizable developed market. This durable approval enables structured commercial rollouts, enhances product credibility with veterinarians, and materially expands the addressable international market beyond the U.S., supporting longer-term revenue diversification.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow indicate the company requires external capital to fund ongoing commercialization and R&D. Continued burn constrains strategic flexibility, forces prioritization of near-term survival over long-term investments, and increases execution risk if SaaS monetization or financing does not materialize on schedule.
Large Operating LossesDeep operating and net losses relative to a small revenue base mean profitability is distant absent scale or a material shift in revenue mix. Even with healthy gross margins, operating expenses are too large versus sales, risking equity erosion and limiting capacity to invest in sales, marketing, and product development without further restructuring or higher-margin recurring revenue.
Dependence On Dilutive FinancingFrequent equity financings with warrants and restricted shares reveal reliance on external capital and raise dilution risk for existing holders. Ongoing financing dependence signals limited internal cash generation and could pressure strategic choices, delay uplisting efforts, and weaken long-term investor alignment if repeated issuances are required to sustain operations.
PetVivo Holdings News
PETV FAQ
What was PetVivo Holdings’s price range in the past 12 months?
PetVivo Holdings lowest stock price was $0.58 and its highest was $1.69 in the past 12 months.
What is PetVivo Holdings’s market cap?
PetVivo Holdings’s market cap is $27.98M.
When is PetVivo Holdings’s upcoming earnings report date?
PetVivo Holdings’s upcoming earnings report date is Jun 25, 2026 which is in 47 days.
How were PetVivo Holdings’s earnings last quarter?
PetVivo Holdings released its earnings results on Feb 17, 2026. The company reported -$0.069 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.069.
Is PetVivo Holdings overvalued?
According to Wall Street analysts PetVivo Holdings’s price is currently Overvalued.
Does PetVivo Holdings pay dividends?
PetVivo Holdings does not currently pay dividends.
What is PetVivo Holdings’s EPS estimate?
PetVivo Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PetVivo Holdings have?
PetVivo Holdings has 35,017,418 shares outstanding.
What happened to PetVivo Holdings’s price movement after its last earnings report?
PetVivo Holdings reported an EPS of -$0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.881%.
Which hedge fund is a major shareholder of PetVivo Holdings?
Currently, no hedge funds are holding shares in PETV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PetVivo Holdings
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PETV Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive strategic and operational narrative: management secured transformative partnerships (exclusive AI licensing, major distributor and channel agreements), advanced R&D and international commercialization (Health Canada recognition, U.K. and Mexico distribution), and materially reduced liabilities (≈81% decline). These developments position the company for a recurring, high-margin SaaS revenue stream (PetVivo AI) that could complement device and biologic sales. Near-term financials remain challenging — modest revenue decline (−2% YoY for nine months), lower gross margins from product mix, ongoing operating losses (net loss $7.5M) and cash burn ($5.3M) leave liquidity and timing risks. Overall, the strategic progress and balance sheet improvements outweigh the current financial headwinds, suggesting a Positive sentiment with execution and monetization of AI and commercialization plans as key drivers to watch.View all PETV earnings summariesTechnical Analysis
Iridex
―
Lifeward
―
Vivos Therapeutics
―
Allurion Technologies
―
Nexalin Technology, Inc.
―
Ownership Overview
41.19% Insiders
0.37% Other Institutional Investors
58.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---